You are here

Article Text

Article menu
Download PDFPDF
Midwifery
Systematic review with meta-analysis
Low-dose aspirin reduces morbidity and mortality in pregnant women at high-risk for preeclampsia
  1. Emmanuel Bujold
  1. Faculty of Medicine, Department of Obstetrics and Gynecology, Université Laval, Centre Mère-Enfant du CHU de Québec, Québec, G1V 4G2, Canada
  1. Correspondence to : Dr Emmanuel Bujold, Faculty of Medicine, Department of Obstetrics and Gynecology, Université Laval, Centre Mère-Enfant du CHU de Québec, Québec, Canada; Emmanuel.bujold{at}crchudequebec.ulaval.ca

https://doi.org/10.1136/ebnurs-2014-101915

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Henderson JT, Whitlock EP, O’Connor E, et al. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive services task force. Ann Intern Med 2014;160:695–703.OpenUrlCrossRefPubMedWeb of Science

    Implications for practice and research

    • Daily low-dose aspirin is recommended from 12 weeks’ gestation and onward to women identified at high-risk for preeclampsia.

    • While women with chronic hypertension or personal history of preeclampsia should receive aspirin during pregnancy, further research leading to first-trimester prediction of preeclampsia in low-risk women should be encouraged.

    Context

    Preeclampsia affects 2–8% of pregnancies and is a leading cause of maternal deaths around the world. It is associated with poor perinatal outcome, primarily due to increased risk of intrauterine growth restriction (IUGR) and medically indicated preterm delivery. Over the last three to four decades, there has been …

    View Full Text

    Footnotes

    • Competing interests None.